The Danish pharmaceutical company announced it is halting two major trials out of an abundance of caution, warning that preliminary findings indicating the medication is completely useless should not be treated as definitive.
The manufacturer confirmed Tuesday it is immediately terminating the phase-three cardiovascular program, stressing that while the sudden abandonment strongly implies the anti-inflammatory pill does not work, further longitudinal observation would theoretically be required to prove a negative. Representatives noted the sample size of the cancellation is currently limited to the two trials they just scrapped, meaning broader extrapolation of the drug's failure carries inherent methodological risks.
A recent paper in the New England Journal of Medicine hypothesized a link between taming inflammation and preventing heart disease. However, experts caution that administering a compound that fails to do either should only be classified as a devastating medical setback after adjusting for confounding variables. Results drawn from a double-blind study of 4,000 subjects revealed a robust association between taking the pill and experiencing no biological changes of any kind.
While the immediate liquidation of a late-stage clinical program often correlates with total therapeutic failure, we must remember that correlation does not necessarily equal causation.
The FDA has issued standard guidance advising physicians not to prescribe the cancelled medication, though agency officials noted this recommendation is largely theoretical since the drug will never be manufactured. Regulators suggest that until further placebo-controlled trials can be permanently suspended, patients should speak with their primary care providers before assuming the nonexistent treatment will not save their lives.